Клинички испитувања за Дебелина во Охајо
46 студии за Дебелина бараат учесници на локации во Охајо.
Градови во Охајо
Официјален текст на студијата (англиски)
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Clinical Trial Investigator Clinical Research Center, Cincinnati
- Velocity Clinical Research - Cincinnati, Cincinnati
Се регрутираФаза 3
Возраст од 18 до 99 · Сите полови · Ажурирано 5.10.2026 · NCT07684235Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Velocity Clinical Research - Cincinnati, Cincinnati
- Velocity Clinical Research - Springdale, Cincinnati
Се регрутираФаза 3
Возраст од 18 до 99 · Сите полови · Ажурирано 5.10.2026 · NCT07684144Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Velocity Clinical Research - Cleveland, Beachwood
- Aultman Hospital, Cardiovascular Consultants, Inc, Canton
- Velocity Clinical Research - Auburn, Cincinnati
- и уште 2
Се регрутираФаза 3
Возраст од 45 до 99 · Сите полови · Ажурирано 5.10.2026 · NCT07037433Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- CTI Clinical Research Center /ID# 282043, Cincinnati
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT07752979A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Centricity Research - Ohio, Columbus
- PriMed Clinical Research, Dayton
Се регрутираФаза 3
Возраст од 8 до 18 · Сите полови · Ажурирано 30.9.2026 · NCT07253285A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Velocity Clinical Research, Cincinnati, Springdale, Cincinnati
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT07783802A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- Midwest Eye Center, Cincinnati
- Velocity Clinical Research, Mt. Auburn, Cincinnati
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07595549Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
- Ohio Clinical Trials, Columbus
Се регрутираФаза 1
Возраст од 18 до 65 · Сите полови · Ажурирано 28.9.2026 · NCT07399678Comparing Reduction With ESD- Versus APC-TORe
- Cleveland Clinic Foundation, Cleveland
Се регрутираДобредојдени се здрави волонтери
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT06131281A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Columbus
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07776509Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
Се регрутираФаза 3
Возраст од 18 до 70 · Сите полови · Ажурирано 24.9.2026 · NCT06937099A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Cleveland Clinic, Cleveland
- Nationwide Children's Hospital, Columbus
Се регрутираФаза 3
Возраст од 6 до 17 · Сите полови · Ажурирано 24.9.2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
Се регрутираФаза 3
Возраст од 18 до 70 · Сите полови · Ажурирано 24.9.2026 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- CTI Clinical Research Center, Cincinnati
- Care Access - Lima, Lima
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07392190A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Care Access - Lima, Lima
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07282600A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- CTI Clinical Research Center, Cincinnati
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 22.9.2026 · NCT07589608A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- CTI Clinical Research Center, Cincinnati
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07369011A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Kent
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07784270A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Cincinnati
- AURORA-2 Clinical Site, Cleveland
- AURORA-2 Clinical Site, Columbus
- и уште 1
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT07743450A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Cincinnati
- AURORA-1 Clinical Site, Cleveland
- AURORA-1 Clinical Site, Columbus
- и уште 1
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT07743463A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Remington Davis Inc, Columbus
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Providence Health Partners-Center for Clinical Research, Dayton
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 14.9.2026 · NCT06897475A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Hometown Urgent Care and Research - Dayton, Dayton
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Columbus
Се регрутираФаза 3Добредојдени се здрави волонтери
Возраст од 18 до 79 · Сите полови · Ажурирано 11.9.2026 · NCT07654374AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- CTI Clinical Research Center, Cincinnati
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 11.9.2026 · NCT07571005AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- CTI Clinical Research Center, Cincinnati
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT07571109A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- PriMED Clinical Research, Dayton
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 8.9.2026 · NCT07215559A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- CTI Clinical Research Center, Cincinnati
Се регрутираФаза 2
Возраст од 18 до 75 · Сите полови · Ажурирано 8.9.2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Optima Research - Boardman, Boardman
Се регрутираФаза 4
Возраст 18 и постари · Сите полови · Ажурирано 4.9.2026 · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Cleveland
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT07284901A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Columbus
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.8.2026 · NCT07784725Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Cincinnati Children's Hospital Medical Center, Cincinnati
Се регрутираФаза 2
Возраст од 7 до 25 · Сите полови · Ажурирано 19.8.2026 · NCT05082519A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Aultman Hospital, Canton
- Lindner Center,Christ Hospital, Cincinnati
- Louis Stokes Clvlnd VA Med Ctr, Cleveland
- и уште 4
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 18.8.2026 · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Columbus
- ACCOMPLISH-1 Research Site, Columbus
Се регрутираФаза 3
Возраст од 18 до 79 · Сите полови · Ажурирано 10.8.2026 · NCT07654361Atomoxetine in Melanocortin Obesity Syndrome
- Nationwide Children's Hospital, Columbus
Се регрутираФаза 2
Возраст 6 и постари · Сите полови · Ажурирано 7.8.2026 · NCT06899178Fibrosis Lessens After Metabolic Surgery
- Cleveland Clinic, Cleveland
Се регрутираФаза 4Добредојдени се здрави волонтери
Возраст од 18 до 75 · Сите полови · Ажурирано 31.7.2026 · NCT06374875Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
- The Ohio State University, Columbus
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 24.7.2026 · NCT07702461A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
- Ohio Clinical Trials, Columbus
Се регрутираФаза 2
Возраст од 18 до 80 · Сите полови · Ажурирано 22.7.2026 · NCT07477704A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants
- Medpace Clinical Pharmacology Unit, Cincinnati
Се регрутираФаза 1Добредојдени се здрави волонтери
Возраст од 18 до 65 · Сите полови · Ажурирано 4.5.2026 · NCT07219589Dietary Peanuts and Nutrition-Related Outcomes
- University Hospitals Cleveland Medical Center, Clevland
Се регрутираДобредојдени се здрави волонтери
Возраст од 18 до 80 · Сите полови · Ажурирано 23.4.2026 · NCT07244458Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.